Loperamide
Imodium (loperamide) is a small molecule pharmaceutical. Loperamide was first approved as Imodium on 1982-01-01. It is used to treat bacillary dysentery, diarrhea, and functional colonic diseases in the USA. The pharmaceutical is active against mu-type opioid receptor.
Download report
Favorite
Top OTC Drugs
Commercial
Trade Name
FDA
EMA
Imodium (generic drugs available since 1991-09-18)
CombinationsImodium multi-symptom (generic drugs available since 1991-09-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Loperamide hydrochloride
Loperamide hydrochloride
+
Simethicone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| IMODIUM MULTI-SYMPTOM RELIEF | Johnson & Johnson | N-021140 OTC | 2000-11-30 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anti-diarrheal | ANDA | 2023-06-14 |
| imodium | ANDA | 2023-03-23 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | D003967 | HP_0002014 | R19.7 | 1 | 2 | 5 | 5 | — | 12 |
| Fecal incontinence | D005242 | R15 | — | 1 | 2 | 1 | 3 | 6 | |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | — | 1 | |
| Clostridioides difficile | D016360 | NCBITaxon_1496 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 9 | 1 | — | — | 11 |
| Colorectal neoplasms | D015179 | — | 3 | 1 | — | — | 4 | ||
| Neoplasms | D009369 | C80 | — | 2 | 1 | — | — | 3 | |
| Non-small-cell lung carcinoma | D002289 | — | 1 | 1 | — | — | 2 | ||
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | 1 | 1 | — | — | 1 |
| Clostridium infections | D003015 | EFO_1000874 | A05.2 | — | 1 | 1 | — | — | 1 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | 1 | — | — | 1 |
| Short bowel syndrome | D012778 | — | — | 1 | — | — | 1 | ||
| Rectal neoplasms | D012004 | — | — | 1 | — | — | 1 | ||
| Dehydration | D003681 | E86.0 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | T88.7 | 1 | 1 | — | — | — | 1 | |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
| Chondrosarcoma | D002813 | — | 1 | — | — | — | 1 | ||
| Alveolar soft part sarcoma | D018234 | — | 1 | — | — | — | 1 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | 1 | — | — | — | 1 | |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | 1 | |
| Triple negative breast neoplasms | D064726 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | 1 | 7 | ||
| Intestinal obstruction | D007415 | K56.60 | 2 | — | — | — | — | 2 | |
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Colitis | D003092 | EFO_0003872 | K52.9 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LOPERAMIDE |
| INN | loperamide |
| Description | Loperamide is a synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease. It has a role as a mu-opioid receptor agonist, an antidiarrhoeal drug and an anticoronaviral agent. It is a member of piperidines, a monocarboxylic acid amide, a member of monochlorobenzenes and a tertiary alcohol. It is a conjugate base of a loperamide(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 53179-11-6 |
| RxCUI | 6468 |
| ChEMBL ID | CHEMBL841 |
| ChEBI ID | 6532 |
| PubChem CID | 3955 |
| DrugBank | DB00836 |
| UNII ID | 6X9OC3H4II (ChemIDplus, GSRS) |
Target
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,249 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,352 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more